Navigation Links
Successful Inspection by the FDA of ENCO Pharmaceutical Development's Cary, NC Facility
Date:2/19/2013

JACKSONVILLE, Fla., Feb. 19, 2013 /PRNewswire-iReach/ -- ENCO Pharmaceutical Development, Inc. (EPDI) is pleased to announce the completion of a successful FDA inspection of its Cary, NC facility.  The 3-day audit included both a general cGMP inspection as well as a directed Pre-approval Inspection (PAI).  This was the first FDA audit of EPDI's Cary facility which opened in 2010.

"We have worked hard over the years to ensure that our quality systems are robust and to foster an atmosphere of compliance within our organization," said Rick Camp , President of EPDI.   Christopher Walker , who manages the Cary facility commented, "It is gratifying to have completed this very thorough audit by the FDA so successfully, particularly since this is a new site for EPDI."

The audit covered thorough reviews of general systems and documentation such as SOP's, test methods and protocols and involved a variety of technical areas including analytical development, release and stability testing and storage.

Upon completion of the inspection, the investigator reported no findings and no Form 483 was issued.

ENCO Pharmaceutical Development Inc. provides a broad spectrum of pharmaceutical development and analytical services from its facilities in Jacksonville, FL and Cary, NC.  The company works with a variety of organizations in both the pharmaceutical and medical device industries, including global, small and mid-size firms, as well as virtual organizations. EPDI provides expertise in formulation development of solid, semi-solid, liquids, ophthalmic and lyophilized dosage forms as well as analytical support for method development and validation, stability studies, raw materials testing, extractable/leachable studies, medical device testing and more. For additional information, please visit www.encopharma.com.

Media Contact: Keith Hurley , ENCO Pharmaceutical Development, Inc.,336-541-3270, khurley@encopharma.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE ENCO Pharmaceutical Development, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Imprimis Announces Successful Results from its Pharmacokinetic Study for its Impracor Topical NSAID
2. Columbia Asia Referral Hospital, Yeshwanthpur, Successfully Conducts HOLEP to Treat a 72-Year-old With Urology Disorder
3. Coyote Pharmaceuticals Initiates GMP Manufacturing Process for CNS-102 Following Successful Pre-IND Meeting
4. Kemwell Announces Successful Pre-NDA US FDA Inspection
5. New Study Introduces Valuable Tool to Aid Doctors and Patients in Choosing Successful Outcomes for Cheek Rejuvenation
6. Braincells, Inc. Announces the Successful Completion of a Multiple Ascending Dose Study of BCI-838, a Group II mGluR2/3 Antagonist, and the Companys Plans for a Proof-of-Concept Study in Patients with Treatment-Resistant Depression
7. Easy on the Stomach: ALCAT Worldwide Sponsors Successful Conference on Gut, Brain & Autoimmune Disorders
8. Omeros Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
9. A Successful Launch of a New Oncology Product Requires Global Teams & Planning
10. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
11. Report Highlights Key Activities that Drive Successful New Product Planning Groups in Pharmaceutical Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) announced ... operating results on Monday, August 7, 2017 after market ... p.m. ET. Shareholders ... of the conference call by dialing 877-201-0168 or 647-788-4901 ... 15 minutes prior to the call. A live webcast ...
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July 21, 2017 ... ) announced today that it will report its second ... Thursday, July 27, 2017. ... July 27, 2017, at 9:00 a.m. Eastern Time.  The ... dialing 1-970-315-0533.  A rebroadcast of the teleconference will be ...
(Date:7/21/2017)... you know that PhRMA member companies invested $65.5 billion in research ... medicines, generics and the supply chain account for 14 percent of ... this (7 percent)? Or that the United States ... in high-growth biopharmaceutical startups? ... The biopharmaceutical industry accounts for ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... SignatureCare Emergency Center ... be awarded for the fall semester to a deserving student. Get your applications ... 2017 scholarship was awarded to Mariana Castillo who is a nursing student at Prairie ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... (MCPS) have partnered together for a unique opportunity that helps high school girls succeed ... “Removing Barriers, Creating Opportunities.” Horizon Goodwill will host over 20 high school ...
(Date:7/24/2017)... , ... July 24, 2017 , ... The International Essential ... life-altering neurological condition called essential tremor (ET). The seminar will take place on Saturday, ... Woods Blvd., Independence, OH. The program will run from 9 a.m. to 12 p.m., ...
(Date:7/24/2017)... ... July 24, 2017 , ... The Topricin Companies, ... awareness for Topricin’s revolutionary, natural, after-burn skin care product, Topricin After Burn Cream. ... of long term skin conditions, including cancer. In the short term, overexposure ...
(Date:7/24/2017)... ... July 24, 2017 , ... Puregraft, the global ... the issuance of United States Patent Number 9,695,398 (the '398 patent) and South ... The '398 and '324 patents cover methods and systems for optimizing fat grafts ...
Breaking Medicine News(10 mins):